# Purple Biotech LTD.: overview PPBT · Nasdaq · CIK 1614744 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ppbt.md) · [Financials](/companies/ppbt/financials.md) · [Filings](/companies/ppbt/filings.md) · [Insiders](/companies/ppbt/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [17568036.00](/filings/0001213900-24-020111.md) | [23.97](/filings/0001213900-25-022192.md) | [17.96](/filings/0001213900-25-022192.md) | [4.99](/filings/0001213900-25-022192.md) | [0.03](/filings/0001213900-26-031365.md) | | Free cash flow | $m | [(0.5)](/filings/0001213900-22-011191.md) | [(16.8)](/filings/0001213900-25-022192.md) | [(19.9)](/filings/0001213900-26-031365.md) | not reported | [(5.7)](/filings/0001213900-26-031365.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ppbt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [SmartHarvest Portfolios, LLC](/funds/2066604.md) | 2026-06-30 | $47.8k | 28,468 | | Added +10,341 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $22.1k | 13,166 | | New +13,166 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $21.6k | 12,847 | | Reduced −40,556 | | [Independent Advisor Alliance](/funds/1696899.md) | 2026-06-30 | $20.0k | 11,901 | | New +11,901 | | [Arax Advisory Partners](/funds/1586767.md) | 2026-06-30 | $2.4k | 1,453 | | New +1,453 | | [RHUMBLINE ADVISERS](/funds/1115418.md) | 2026-06-30 | $1.4k | 856 | | Added +146 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $1.3k | 751 | | Added +652 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $331 | 197 | | Reduced −381 | | [HRT FINANCIAL LP](/funds/1475597.md) | 2026-06-30 | $24 | 14,640 | | New +14,640 | | [NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO](/funds/1141802.md) | 2026-06-30 | $13 | 8 | | Unchanged | ## Recent filings [All 574 filings](/companies/ppbt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-05 | 20:38 ET | [6-K](/filings/0001213900-26-106852.md) | Report of a foreign private issuer, period 2026-10-05 | 0001213900-26-106852 | | 2026-09-09 | 20:01 ET | [6-K](/filings/0001213900-26-098378.md) | Report of a foreign private issuer, period 2026-09-09 | 0001213900-26-098378 | | 2026-09-02 | 11:33 ET | [6-K](/filings/0001213900-26-096443.md) | Report of a foreign private issuer, period 2026-09-02 | 0001213900-26-096443 | | 2026-08-10 | 20:03 ET | [6-K](/filings/0001213900-26-087226.md) | Report of a foreign private issuer, period 2026-08-10 | 0001213900-26-087226 | | 2026-08-07 | 11:03 ET | [6-K](/filings/0001213900-26-086393.md) | Report of a foreign private issuer, period 2026-08-07 | 0001213900-26-086393 | | 2026-07-29 | 20:05 ET | [6-K](/filings/0001213900-26-082792.md) | Report of a foreign private issuer, period 2026-07-29 | 0001213900-26-082792 | | 2026-06-23 | 13:28 ET | [6-K](/filings/0001213900-26-070884.md) | Report of a foreign private issuer, period 2026-06-23 | 0001213900-26-070884 | | 2026-06-11 | 11:02 ET | [6-K](/filings/0001213900-26-067548.md) | Report of a foreign private issuer, period 2026-06-11 | 0001213900-26-067548 | | 2026-05-15 | 11:02 ET | [6-K](/filings/0001213900-26-057119.md) | Report of a foreign private issuer, period 2026-05-15 | 0001213900-26-057119 | | 2026-04-27 | 11:15 ET | [6-K](/filings/0001213900-26-047709.md) | Report of a foreign private issuer, period 2026-04-27 | 0001213900-26-047709 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-031365.md), filed Mar 19, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1614744 - Tickers: PPBT - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: L3 - Filer category: Non-accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.